Close Menu

NEW YORK – Janssen Pharmaceutical on Monday said it has begun a rolling submission of its biologics license application for the multiple myeloma CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) with the US Food and Drug Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.